Last reviewed · How we verify

Bupivacaine supraclavicular block

Jose Soberon, MD · FDA-approved active Small molecule

Bupivacaine supraclavicular block is a Local anesthetic (amide) Small molecule drug developed by Jose Soberon, MD. It is currently FDA-approved for Regional anesthesia for upper extremity surgery via supraclavicular brachial plexus block, Pain management in perioperative settings.

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia.

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia. Used for Regional anesthesia for upper extremity surgery via supraclavicular brachial plexus block, Pain management in perioperative settings.

At a glance

Generic nameBupivacaine supraclavicular block
SponsorJose Soberon, MD
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that penetrates nerve sheaths and reversibly binds to voltage-gated sodium channels from the intracellular side, inhibiting sodium influx. When administered as a supraclavicular block, it anesthetizes the upper trunk and divisions of the brachial plexus, providing regional anesthesia for upper extremity surgery. The drug's lipophilicity and protein binding contribute to its prolonged duration of action compared to shorter-acting local anesthetics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine supraclavicular block

What is Bupivacaine supraclavicular block?

Bupivacaine supraclavicular block is a Local anesthetic (amide) drug developed by Jose Soberon, MD, indicated for Regional anesthesia for upper extremity surgery via supraclavicular brachial plexus block, Pain management in perioperative settings.

How does Bupivacaine supraclavicular block work?

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia.

What is Bupivacaine supraclavicular block used for?

Bupivacaine supraclavicular block is indicated for Regional anesthesia for upper extremity surgery via supraclavicular brachial plexus block, Pain management in perioperative settings.

Who makes Bupivacaine supraclavicular block?

Bupivacaine supraclavicular block is developed and marketed by Jose Soberon, MD (see full Jose Soberon, MD pipeline at /company/jose-soberon-md).

What drug class is Bupivacaine supraclavicular block in?

Bupivacaine supraclavicular block belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is Bupivacaine supraclavicular block in?

Bupivacaine supraclavicular block is FDA-approved (marketed).

What are the side effects of Bupivacaine supraclavicular block?

Common side effects of Bupivacaine supraclavicular block include Transient paresthesia, Nerve injury (temporary or permanent), Vascular puncture/hematoma, Systemic toxicity (CNS and cardiac effects at high plasma levels), Horner's syndrome.

What does Bupivacaine supraclavicular block target?

Bupivacaine supraclavicular block targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related